Month: May 2022

Release – Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Posted on by Admin



Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Research, News, and Market Data on Baudax Bio


MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 1,646,091 shares of its common stock, at a purchase price of $1.215 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to 1,646.091 shares of its common stock.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The warrants have an exercise price of $1.09 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about May 19, 2022, subject to the satisfaction of customary closing conditions.

The gross proceeds from the offering are expected to be approximately $2.0 million before deducting placement agent fees and other offering expenses. Baudax Bio currently intends to use the net proceeds from the offering for the commercialization of ANJESO®, pipeline development activities and general corporate purposes.

The shares of common stock described above (but not the warrants or shares of common stock underlying the warrants) are being offered by the Company in a registered direct offering pursuant to an effective “shelf” registration statement on Form S-3 (Registration No. 333-253117), including an accompanying base prospectus previously filed with the Securities and Exchange Commission (the “SEC”) on February 16, 2021 which became effective on September 2, 2021. The offering of such shares of common stock is being made only by means of a prospectus supplement that forms a part of the registration statement. A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and the accompanying base prospectus may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 1002, by phone at (212) 856-5711 or e-mail at 
placements@hcwco.com.

The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About
Baudax Bio

Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.

Forward
Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,” “intend,” and “expect,” and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. Forward-looking statements may include, without limitation, statements regarding the expected completion and use of proceeds of the offering. These forward-looking statements are based on information available to Baudax Bio as of the date of publication on this internet site, including statements relating to the expected completion and use of proceeds of the registered direct offering, and are subject to a number of risks, uncertainties, and other factors that could cause Baudax Bio’s performance to differ materially from those expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, among other things, risks related to market and other conditions, the ongoing economic and social consequences of the COVID-19 pandemic, Baudax Bio’s ability to advance its current product candidate pipeline through pre-clinical studies and clinical trials, Baudax Bio’s ability to raise future financing for continued development of its product candidates such as BX1000, BX2000 and BX3000, Baudax Bio’s ability to pay its debt and satisfy conditions necessary to access future tranches of debt, Baudax Bio’s ability to comply with the financial and other covenants under its credit facility, Baudax Bio’s ability to manage costs and execute on its operational and budget plans, Baudax Bio’s ability to achieve its financial goals; and Baudax Bio’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection. These forward-looking statements should be considered together with the risks and uncertainties that may affect Baudax Bio’s business and future results included in Baudax Bio’s filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

CONTACT:

Investor Relations Contact:
Argot Partners
Sam Martin / Kaela Ilami
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com 


Pyxis Tankers (PXS) – Disappointing results following drop in utilization

Posted on by Admin

Wednesday, May 18, 2022

Pyxis Tankers (PXS)
Disappointing results following drop in utilization

We currently own a modern fleet of five tankers engaged in seaborne transportation of refined petroleum products and other bulk liquids. We are focused on growing our fleet of medium range product tankers, which provide operational flexibility and enhanced earnings potential due to their “eco” features and modifications. We are positioned to opportunistically expand and maximize our fleet due to competitive cost structure, strong customer relationships and an experienced management team whose interests are aligned with those of its shareholders. For more information, visit: http://www.pyxistankers.com.

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

First quarter results were weak. Pyxis reported a 10% decline in Time Charter Equivalent (TCE) revenues in the 2022-1Q versus 2021-1Q due primarily to lower fleet utilization and a jump in voyage-related costs and commissions. TCE revenues of $3.8m were below our estimate of $5.8m. Fleet utilization decreased to 74% from 100% due, in part, to the accidental grounding of a tanker.  Voyage costs ($3.1m versus $1.0m) rose due to increased use of spot employment and higher bunker fuel cost resulting from the drop in utilization.

Lower revenues mean lower cash flow generation. Adjusted EBITDA in the first quarter was ($0.7)m versus $0.8m for the same period last year. We had been expecting EBITDA of $2.1 million. Net income was ($3.4m)/($0.09) per share versus ($2.0m)/($0.07) per share. Our estimate was ($1.9m)/($0.04) per share. Excluding nonrecurring losses from the sale of a vessel and losses from debt extinguishment, net income would have been ($2.9m)/($0.08) per share, still a larger loss than anticipated….

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

FDA Program May Help Investors Uncover Breakthrough Medical Technology

Posted on by cpatches

The FDA Breakthrough Devices Program may be a starting point for investors exploring the medical space. It’s designed to create a quicker path for medical devices that provide more effective treatment or diagnosis of life-threatening or irreversible conditions. There are significant benefits for the companies granted access to the program. Lists of devices after the companies have been granted a marketing authorization are available on the FDA website.

While new pharmaceuticals tend to grab headlines quicker than devices, investors looking for public companies, that may be uncorrelated to the pace of US economic growth or the financial markets, may visit the website and then research the companies on Channelchek.

Image Credit: US Food and Drug Administration (Flickr)

Benefits of the Breakthrough Devices Program

The purpose of the Breakthrough Devices Program is to provide patients and health care providers with timely access to novel medical devices by speeding up their development, assessment, and review. At the same time, it preserves the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with the Agency’s mission to protect and promote public health.

Manufacturers have the opportunity to interact with the FDA’s experts through several different program options to efficiently address issues that present themselves during the FDA premarket review phase. This feedback from the FDA helps shorten the agreement phase. The company can also expect a prioritized review of its submission. This can have the effect of speeding the product to market with less cost and fewer problems.

How this Works

Pulling an example from the Channelchek library of videos from NobleCon18, we can use Perimeter Medical Imaging AI (PYNKF) to understand what a candidate looks like and how it may bring value to the patient, medical provider, and possibly investors.

Perimeter is an early-stage medical device company that expects its flagship product to address unmet cancer treatment needs. Initially, the device is expected to change the way breast cancer is treated and evaluated to improve outcomes and minimize the chance of recurrence or having to reoperate. In order to apply for the FDA designation, Perimeter’s device was indicated for breast cancer. However, the applications are expected to extend well beyond and into other major cancers in the $3.7 billion total market.

This FDA designation makes for a much more clear regulatory pathway. Perimeter meets the first guideline in that its product has unique technology (breakthrough) that is solving problems with a different method on a scalable platform. The procedures are expected to reduce the cost to patients, minimize the need for repeat surgery and be self-funding from the hospitals’ standpoint. This is because about 20 to 25% of cancer patients now need to return for a re-operation that costs approximately $16,000. Hospitals that adopt the Perimeter AI technology could serve patients better and stand to recover their costs while reducing overall patient costs on average.

Take-Away

There are many ways to uncover companies that are “on the move.” Reviewing those the FDA is likely to help along toward a full “go-ahead” is just one of them. For a more detailed look at Perimeter, their unique business model,  and technology, watch the 20-minute video below. For more on understanding the FDA Breakthrough Device Program in order to uncover companies that could change medicine, go to FDA.gov .

To evaluate small and growing companies, explore Channelchek beginning here.

Paul Hoffman

Managing Editor, Channelchek

Michael Burry’s Stock Market Holdings (Filed May 16, 2022)

Posted on by Admin 


Image Credit: Pixabay (Pexels)


Michael Burry’s Latest Portfolio Brings the FAANGS Out

On Monday, May 16, Michael Burry filed his company’s holdings report with the SEC. Relative to the previous quarter, there was significant reshuffling. While it’s rare to get an explanation of his thinking beyond an occasional tweet of warning or tweet of frustration, his quarterly positions report is worth reviewing. It lends a rare clue as to what the celebrated hedge fund manager is expecting.

Michael Burry’s thinking, reflected in Scion Asset Management’s 13F holdings (a/o March 31), are shown below. Following the holdings we offer company descriptions and some thinking related to a few of the holdings.


Source: WhaleWisdom

Why it Matters

The positions in Scions portfolio are usually few, quite deliberate, and not the result of herd thinking. During the prior quarter (Q4 2021), among the scant positions were two public prison stocks ($GEO and $CXW). While many pundits and YouTube “gurus” hazarded a guess as to what Burry may have expected to occur with crime, the positions may have had nothing to do with an expected need for jail cells. Following the stock tickers links above to the Channelchek reports discloses that public policy on for-profit prisons is in flux. The positions may have just been a play on policy direction.

Burry’s investment universe is broader than the average self-directed investor and even deeper than the average hedge fund manager. The positions report reflect just those required to be disclosed in an SEC 13F filing. With this in mind, out of the entire universe of public securities Scion could hold, there are only a dozen that Burry’s portfolio felt were worthy at the end of the first quarter. One is a Put position which effectively makes him short the stock and possibly expecting more red than green, but not necessarily.

 

 

Holdings Breakdown

Scion has a Put on Apple (AAPL) with contracts to control 206,000 shares. The portfolio is also long shares of two other megacap high-tech stocks adding to a similar notional amount. Of the three, based on price earnings ratio, Apple is by far the most expensive. Apple’s P/E is at 23.7 earnings, while Google/Alphabet (GOOGL) is trading at a much lower PE of 20.7x, and Facebook/Meta (FB) is even lower yet at 15.1x price to earnings. This AAPL Put may not be a bet against Apple as much as it is a play that FAANG stocks should trade with multiples more in-line with each other. If this is the case, he’s not looking to hit a home run, but instead looking for movement either down by Apple, or up by the two other FAANG stocks to net incremental capital gains.

Since the 4Q of 2021, he has held Bristol Myers Squibb (BMY).  Year-to-date 2022 the biopharmaceutical company is up 19% vs the S&P 500 which is down 9.8%. Discover Network C shares (DISCK) is his fourth largest by market value. The C shares of Discovery allow no voting rights. Discovery’s A shares allow one vote per share, and B shares 10 votes per share.

Moving down the list shows a very diversified portfolio of long positions including Cigna (CI) a health care insurer, Ovintiv (OVV) a Canadian based fossil fuel company trading at 8x earnings, and Nexstar Media (NXST) which is a media company that owns television broadcast networks not unlike DISCK.

Stellantis NV (STLA) is a Dutch automaker trading on the NYSE and London exchanges. It owns the Chrysler and Jeep brands as well as Alpha Romeo, Peugeot, and Maserati. STLA pays above-average annual dividends. It declared a dividend on February 25, with an ex-dividend date of April 19. The period covered in Scion’s 13F is through March 31. 

In the consumer discretionary category Scion’s portfolio held two companies month-end that stand to benefit as consumers fill their need to travel and play outdoors. Bookings.com (BKNG) which is a huge online travel website and retailer Sportsman’s Warehouse (SPWH) which is a small-cap value stock trading at only 3.75x earnings.

The last is a payment tech company called Global Payments (GPN). The company’s product line runs the full gamut of electronic merchant payment products.

 Take-Away

Dr. Michael J. Burry has an excellent record of spotting investment opportunities before the rest of the market. His picks are as disparate as the mortgage market in 2008 and GameStop (GME) in 2020.

The portfolio reported by the SEC on May 16, reflecting March 31 quarter-end holdings does not have a strong theme. The most talked-about position has been the Puts on Apple. As mentioned, that play may be more complicated and be a hedge involving other long holdings.

Sign-up to receive Channelchek updates in your inbox.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Michael Burry Sees Positive in Elon Musk’s Twitter Stake

Why Michael Burry has Better Opportunity Than Cathie Wood




Is the Index Bubble Michael Burry Warned About Still Looming?

Michael Burry’s Stock Market Holdings (Filed Feb 14, 2022)

Sources

https://www.sec.gov/Archives/edgar/data/0001768023/000156761922010751/xslForm13F_X01/primary_doc.xml

https://whalewisdom.com/filer/scion-asset-management-llc#tabholdings_tab_link

www.koyfin.com

Stay up to date. Follow us:

 

Tokens.com Corp. (SMURF) – First Quarter Results

Posted on by Admin

Tuesday, May 17, 2022

Tokens.com Corp. (SMURF)
First Quarter Results

Tokens.com Corp is a publicly traded company that invests in Web3 assets and businesses focused on the Metaverse, NFTs, DeFi, and gaming based digital assets. Tokens.com is the majority owner of Metaverse Group, one of the world’s first virtual real estate companies. Hulk Labs, a wholly-owned Tokens.com subsidiary, focuses on investing in play-to-earn revenue generating gaming tokens and NFTs. Additionally, Tokens.com owns and stakes crypto assets to earn additional tokens. Through its growing digital assets and NFTs, Tokens.com provides public market investors with a simple and secure way to gain exposure to Web3.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q22 Results. Tokens.com reported revenue of $326,320 in the first quarter of 2022, flat sequentially. We had estimated revenue of $550,000. The operating loss was $631,856 in the quarter, compared to an operating loss of $3.0 million in the fourth quarter of 2021, which was impacted by higher professional fees and listing expenses. Tokens.com reported net income for the quarter of $7.8 million, or $0.08 per share, driven by a gain on the revaluation of warrant liability.

Moving Forward. Tokens.com continues to make inroads in the Web 3.0 universe. The Metaverse Group had a successful Fashion Week and is now generating revenue from leases. Hulk Labs has been successfully launched in the play-to-earn gaming space. And Tokens.com continues to stake various cryptos.…

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Motorsport Games (MSGM) – Moving Forward At A Slightly Slower Speed

Posted on by Admin

Tuesday, May 17, 2022

Motorsport Games (MSGM)
Moving Forward At A Slightly Slower Speed

Motorsport Games, a Motorsport Network company, combines innovative and engaging video games with exciting esports competitions and content for racing fans and gamers around the globe. The Company is the officially licensed video game developer and publisher for iconic motorsport racing series across PC, PlayStation, Xbox, Nintendo Switch and mobile, including NASCAR, INDYCAR, 24 Hours of Le Mans and the British Touring Car Championship (“BTCC”). Motorsport Games is an award-winning esports partner of choice for 24 Hours of Le Mans, Formula E, BTCC, the FIA World Rallycross Championship and the eNASCAR Heat Pro League, among others.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Favorable Q1 results. The company reported strong Q1 revenue of $3.3 million, 95% higher than our estimate of $1.7 million. Adj. EBITDA loss of $5.55 million was in line with our forecast. The company benefited from diversified revenue in the quarter, with 27% of total revenue coming from rFactor 2 and esports. The revenue diversification demonstrates the company’s ability to derive value from more than just its NASCAR franchise.   

Product roadmap changes. Management noted that the company will focus on console and PC games in the near term given strong demand in those areas. Additionally, the company will not release a new NASCAR Ignition title this year, opting to release an expansion pack to the current title instead. Release of the next iteration of the game is planned for mid-2023….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Price Moves When Warren Buffett Buys and Sells (Based on May 16 SEC Filing)

Posted on by Admin 


Image Credit: Fortune Live Media (Flickr)


The Big Price Impact on Stocks After Warren Buffett’s Most Active Buying Spree

Warren Buffett and Berkshire Hathaway (BRK.A, BRK.B) were actively spending down the company’s large pool of cash last quarter, just as they promised during their recent annual meeting. This makes sense as some stock prices are lower than they have been in years, and a few sectors are showing they could have plenty of upside potential. It makes even more sense when you consider that Berkshire Hathaway was sitting on $144 billion in cash. The inflation rate is now running above 8% and eroding the value of every unearning penny.

Jumping into the market can be costly if wrong, but investor’s ‘dry powder’ is being eroded with increased costs by the day – finding a place for money to grow by at least the inflation rate would seem prudent. The analysts at Berkshire Hathaway are certainly aware of this.

The positive impact of Berkshire showing confidence in a company is often all that is needed to exceed the near non-earnings holding a cash position. Below we look at three Berkshire Hathaway changed positions as reported on May 16, and then compare the stock’s price moves versus the overall market.

Where Did They Gain Exposure

As revealed by the companies 13F filed on May 16, as of March 31 Berkshire Hathaway added Citigroup (C), Paramount Global (PARA), and sold Verizon (VZ). There were older positions added to as well, such as Chevron (CVX), and Activision Blizzard (ATVI). But for the purpose of showing the power of Buffett’s believing a stock is attractive, or in Verizon’s case, no longer attractive, we’ll take a look at the market moves of these companies as of 1pm the day after the 13F was made public.


Source: Koyfin

The above chart of Citibank, Paramount Global, and
Verizon from the beginning trading on Monday compares the stocks to the S&P
500 performance during the same short period.

 

The S&P, as reflected during the short period in this chart, beginning on the date of Berkshire’s 13F filing, shows the S&P 500 up 1.60%. This is substantial in a year when the index has mostly been delivering red to investors. Verizon was the most noteworthy sale of Buffett as they brought their position near zero. The company’s stock rose only 0.11%, well below the S&P benchmark performance.

As for the positions opened during the first quarter by Berkshire Hathaway, Citicorp shot up 8.28%. Paramount Global reacted even more strongly, rising double digits to 13.95%. 

Lessons

While an SEC-registered portfolio new holdings are kept close to the vest before reported in order to avoid insider trading problems, listening to what someone like Warren Buffett is saying at annual meetings and at other times can allow you to get a sense if they have been active, and in what industries. More important, is whether they are active buying or selling. For an investor that is holding a stock which a well-followed investor has decided to sell, can cause significant underperformance for at least the near term.

Other Pertinent Info from the 13F Filing

During the first quarter of 2022, the value of Berkshire’s US stock portfolio rose by 10% to $364 billion. Buffett had indicated the firm he manages has been struggling to find bargains in recent years. He blamed this on stocks swelling to record highs, fierce competition from private equity firms, and SPACs which increased competition and costs of acquisitions. Even Berkshire’s own rising stock price made it unappealing as a company stock buy-back.

A change of appetite took place in the first quarter of 2022. Berkshire bought $51 billion worth of equities and sold less than $10 billion in stocks. Its net cash reduction of $41 billion helped slash its cash pile by 28% to $106 billion. Q1 2022 marked one of the most active buying periods in Berkshire Hathaway’s history.

Take-Away

Well known, successful investors can either make a winner out of your holding or cause it to trade at a pace below the market. While knowing and trading on information before it is made public can get you in trouble, investors like Buffett do provide guidance. These hints as to their thinking and likely direction may help investors somewhat. This is why it always makes sense to know what they’re saying – it isn’t fun holding something they just reported sold, and the tailwind they create when you’re long the same company can be profitable.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Using Warren Buffett’s SEC Filing as an Oracle

Cathie Wood Says Benchmark Funds are Where the Risk Is




Is the SEC conducting “Unfounded Investigations” of Elon Musk?

Warren Buffett vs Elon Musk, Who’s Right?

Sources

https://www.sec.gov/Archives/edgar/data/1067983/000095012322006442/xslForm13F_X01/primary_doc.xml

https://whalewisdom.com/filer/berkshire-hathaway-inc#google_vignette

www.koyfin.com

Stay up to date. Follow us:

 

Voyager Digital (VYGVF) – Announces $60 Million Raise; Reports 3Q22 Results

Posted on by Admin

Tuesday, May 17, 2022

Voyager Digital (VYGVF)
Announces $60 Million Raise; Reports 3Q22 Results

Voyager Digital Ltd.’s (TSX: VOYG) (OTCQX: VYGVF) (FRA: UCD2) US subsidiary, Voyager Digital, LLC, is a fast-growing cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost-efficiency to the marketplace. Voyager offers a secure way to trade over 100 different crypto assets using its easy-to-use mobile application. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

3Q22 Results. Voyager reported $102.7 million of revenue for 3Q22, in-line with the $100-$105 million guidance. Trading revenue was off sharply sequentially as trading volume fell, partially offset by merchant services and staking revenue. We had projected revenue of $98 million. Operating loss was $43.2 million compared to our $32.7 million estimate. Voyager reported a net loss of $61.4 million for the quarter, or $0.36 per share, versus our $0.15 estimate.

Key Metrics for the Third Quarter. Total funded accounts reached 1.190 million, a sequential increase of 115,000 from 1.075 million in the second quarter. Total verified users increased by 255,000 to 3.486 million from 3.231 million in the second quarter, while net new deposits decreased by $642 million to $395 million from the previous quarter’s $1.04 billion….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Ayala Pharmaceuticals (AYLA) – Data Milestones Reiterated With 1Q22 Financial Report

Posted on by Admin

Tuesday, May 17, 2022

Ayala Pharmaceuticals (AYLA)
Data Milestones Reiterated With 1Q22 Financial Report

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations. AL102 is currently in a Pivotal Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q22 Reported With Clinical Updates.   Ayala Pharmaceuticals reported a 1Q22 loss of $10.0 million or $(0.66) per share.  Interim results from the Phase 2/3 RINGSIDE trial testing AL102 in desmoid tumors are expected to be announced in mid-2022, unchanged from previous guidance.  The company also expected to provide updates from the Phase 2 ACCURACY trial testing AL102 in adenoid cystic carcinoma (ACC), and plans to begin a trial in acute lymphoblastic leukemia (ALL) later in 2022.  The company ended the quarter with $27.4 million in cash.

Looking Forward To Phase 2/3 Ringside Data.  The RINGSIDE trial is testing AL102 for treatment of desmoid tumors, a rare tumor of the connective tissue.  In February, Ayala announced that Part A of the trial had completed enrollment of 42 patients to evaluate the safety and tolerability, as well as tumor shrinkage at 16 weeks.  Upon completion of Part A, the double-blind placebo-controlled Part B will begin testing efficacy with a target enrollment of 156 patients….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – PDS Biotech to Participate at Upcoming Investor Conferences

Posted on by Admin



PDS Biotech to Participate at Upcoming Investor Conferences

Research, News, and Market Data on PDS Biotech

FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that its management will present at the H.C. Wainwright Global Investment Conference and the LD Micro Invitational and will participate at the UBS Healthcare Virtual One-on-One Day. 

H.C. Wainwright Global Investment Conference
Date: Tuesday, May 24, 2022
Time: 7:00 AM EDT
Investors can register for the conference here

UBS Healthcare Virtual One-on-One Day
Date: Wednesday, June 1, 2022

LD Micro Invitational Conference
Date: Wednesday, June 8, 2022
Time: 7:30 AM PDT
Virtual Viewers: Livestream

Following the conferences, a webcast replay of the presentations will be available on the Investor section of the company’s website, PDS Biotechnology. 

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.

Our Infectimune™ -based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Investor
Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838

pdsb@cg.capital


CoreCivic, Inc. (CXW) – The New Day Has Begun; Announces $150 Million Share Repurchase Authorization

Posted on by Admin

Tuesday, May 17, 2022

CoreCivic, Inc. (CXW)
The New Day Has Begun; Announces $150 Million Share Repurchase Authorization

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for nearly 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Repurchase Authorization. According to an 8-K filed yesterday, on May 12, 2022, the Board of Directors of CoreCivic Inc. approved a share repurchase program authorizing the Company to repurchase up to $150 million of the Company’s common stock. The authorization is above our projected $100 million plan and represents approximately 11% of Monday’s closing market capitalization.

Program Details. Repurchases of the Company’s outstanding common stock may be made at management’s discretion from time to time in the open market, through privately negotiated transactions, or otherwise. The share repurchase program has no time limit and does not obligate the Company to purchase any particular amount of its common stock….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Garibaldi Resources Corp (GGIFF) – Setting Up for a Productive 2022 Drilling Program

Posted on by Admin

Monday, May 16, 2022

Garibaldi Resources Corp (GGIFF)
Setting Up for a Productive 2022 Drilling Program

Garibaldi Resources Corp. is an active Canadian-based junior exploration company focused on creating shareholder value through discoveries and strategic development of its assets in some of the most prolific mining regions in British Columbia and Mexico.

Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Outstanding Casper drill results. Garibaldi Resources released results from exploratory drill holes testing multiple mineralized veins and volcanic rocks at the Casper Quartz Vein System. Five diamond drill holes followed the first four holes for which results were released in February 2021. Eight of the nine holes have intersected significant gold mineralization, with increasing gold grades toward the southeast.

Promising Nickel Mountain target. Building on the company’s 2021 Z-Axis Tipper Electromagnetic (ZTEM) survey that encompassed Garibaldi’s 180-square kilometer Nickel Mountain – Palm Springs Project claim groups, three-dimensional processing identified several new low-resistivity ZTEM responses 5 kilometers northeast of the E&L nickel-copper-cobalt massive sulphide zone, including a new anomaly at the B1 target which has not been drill tested. The B1 target exhibited a consistent ZTEM low resistivity zone coincident with a near surface VTEM conductive anomaly. The ZTEM low resistivity zone extends to depth like the low resistivity zone beneath E&L….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

One Stop Systems (OSS) – Keep on Truckin’

Posted on by Admin

Monday, May 16, 2022

One Stop Systems (OSS)
Keep on Truckin’

One Stop Systems, Inc. (OSS) designs and manufactures innovative AI Transportable edge computing modules and systems, including ruggedized servers, compute accelerators, expansion systems, flash storage arrays, and Ion Accelerator™ SAN, NAS, and data recording software for AI workflows. These products are used for AI data set capture, training, and large-scale inference in the defense, oil and gas, mining, autonomous vehicles, and rugged entertainment applications. OSS utilizes the power of PCI Express, the latest GPU accelerators and NVMe storage to build award-winning systems, including many industry firsts, for industrial OEMs and government customers. The company enables AI on the Fly® by bringing AI datacenter performance to ‘the edge,’ especially on mobile platforms, and by addressing the entire AI workflow, from high-speed data acquisition to deep learning, training, and inference. OSS products are available directly or through global distributors. For more information, go to www.onestopsystems.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q22 Results. One Stop Systems reported record first quarter revenue of $17.1 million, up 28% y-o-y and above management’s $16.8 million guide. We had forecast $16.8 million. GAAP net income of $579,200, or $0.03 per share, versus net income of $41,300, or breakeven per share, last year. Adjusted net income of $978,000, or $0.05 per share, versus $644,000, or $0.03 per share in 1Q21. We had forecast $0.02 and $0.04 respectively.

Disguise, Bressner Driving Results. OSS’s media and entertainment client, Disguise had a record revenue quarter for OSS, with revenue now greater than the pre-COVID environment. The return of in-person events accounted for a significant portion of the revenue increase. Bressner revenue increased 37% y-o-y, driven by ongoing improvement in the European economy as COVID impacts diminish.…

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.